Ubeslo / Obicetrapib for Primary Hypercholesterolaemia and Mixed Dyslipidaemia

As of August 2026, MARA’s assessment finds Ubeslo / Obicetrapib’s reimbursement risk concentrated in uncertainty, sensitivity, and broader impacts, with care pathway integration a strength; the current MARA Rating and full rationale are available in the report.

The assessment also weighs clinical effectiveness: how much additional benefit the drug demonstrated over the care patients already receive — the first question every payer asks. The strength recorded in care pathway integration carries weight because that domain asks how the drug fits into the way care is organised today; a treatment that demands new infrastructure or displaces an established pathway faces extra scrutiny.

Cardiology

This rating sits within MARA’s Cardiology coverage, alongside 24 other independently assessed treatments in the same area.

What payers will ask

Is the clinical benefit the kind payers reward? — Clinical effectiveness

Obicetrapib provides additional LDL-C lowering on top of background lipid therapy with consistent results across multiple phase 3 trials. However, the evidence is primarily based on surrogate endpoints (LDL-C lowering) rather than direct cardiovascular outcomes.

Does the economic case hold at the expected price? — Cost effectiveness

Economic evidence is immature with no current market-specific ICER or comprehensive economic model based on phase 3 data.

Is there quality-of-life evidence payers weigh? — Quality of life

No obicetrapib-specific HRQoL data or validated instruments were reported in the pivotal evidence base.

Does the safety profile hold up for payers? — Safety and Adverse Effects

Pooled phase 3 safety data show comparable adverse event rates between obicetrapib and placebo over one year, with no major safety signals identified.

Was the drug compared against what payers expect? — Comparator Selection

TANDEM trial included ezetimibe as an active comparator, which is relevant to current practice, although not all key comparators were included.

Is the population defined the way payers need it? — Patient Population and Subgroups

The trials represent high-risk populations with ASCVD and/or HeFH, but broader populations such as primary prevention and Japanese long-term treatment are less represented.

Does the drug fit how care is delivered and paid for? — Care Pathway Integration

Obicetrapib is an oral, once-daily medication that fits well into existing lipid-lowering therapy pathways with minimal disruption.

Are the wider system costs understood? — Resource Use and Cost Implications

No budget-impact or resource information is presented, and no market-specific cost data are available.

Would the evidence survive payer scrutiny? — Evidence Quality and Robustness

The evidence is based on multiple randomized, double-blind phase 3 studies with consistent results for LDL-C lowering, but lacks long-term cardiovascular outcomes.

How exposed is the case to uncertainty? — Uncertainty, Sensitivity, and Broader Impacts

High uncertainty remains regarding cardiovascular outcomes, long-term safety, and economic value due to incomplete data.

Request the current rating

Be alerted when this rating changes:

Related Reimbursement Risk Assessments

Full Legal Disclaimer and Usage Terms

The MARA Rating® is an independent opinion of a drug’s market access pharma risk profile and is provided for informational purposes only—not as investment, medical, legal or any other type of advice. See our full disclaimer here.